心肌保护
泛素
蛋白酶体
地高辛
药理学
细胞生物学
化学
蛋白质降解
再灌注损伤
医学
缺血
生物
内科学
心力衰竭
生物化学
基因
作者
Manjula Vinod,Alexandre Berthier,Xavier Maréchal,Céline Gheeraert,Raphaël Boutry,Stéphane Delhaye,Jean‐Sébastien Annicotte,Hélène Duez,Agnès Hovasse,Sarah Cianférani,David Montaigne,Jérôme Eeckhoute,Bart Staels,Philippe Lefèbvre
标识
DOI:10.1038/s44161-022-00148-z
摘要
Myocardial ischemia–reperfusion injury (MIRI) induces life-threatening damages to the cardiac tissue, and pharmacological means to achieve cardioprotection are sorely needed. MIRI severity varies along the day–night cycle and is molecularly linked to components of the cellular clock, including the nuclear receptor REV-ERBα, a transcriptional repressor. Here we show that digoxin administration in mice is cardioprotective when timed to trigger REV-ERBα protein degradation. In cardiomyocytes, digoxin increases REV-ERBα ubiquitinylation and proteasomal degradation, which depend on REV-ERBα’s ability to bind its natural ligand, heme. Inhibition of the membrane-bound Src tyrosine-kinase partially alleviated digoxin-induced REV-ERBα degradation. In untreated cardiomyocytes, REV-ERBα proteolysis is controlled by several E3 ubiquitin ligases and the proteasome subunit PSMB5. Among these, only SIAH2 and PSMB5 contributed to digoxin-induced degradation of REV-ERBα. Thus, controlling REV-ERBα proteostasis through the ubiquitin–proteasome system is an appealing cardioprotective strategy. Our data support the timed use of clinically approved cardiotonic steroids in prophylactic cardioprotection. The heart’s tolerance to ischemia–reperfusion injury varies according to a day–night cycle. Vinod et al. show that a timed low dose of cardiac glycosides, such as digoxin, is protective against heart ischemia–reperfusion injury by promoting the proteasomal degradation of the molecular-clock component and transrepressive nuclear receptor REV-ERBα.
科研通智能强力驱动
Strongly Powered by AbleSci AI